Exporter, Buying House
Weith Pharmaceutical (Shanghai) Technology Co., Ltd
Claim Your Company
China,Shanghai
Average Lead Time: 10 days
Annual Revenue: Above US$100 Million
Membership Year: 1998
Plant Area:
50,000-100,000 square meters
Accepted Payment Modes:
USD, EUR, HKD
Certification:
GMP/ISO, GMP/ISO
Main Products:
Adapalene
, Amorolfine HCL , Posaconazole , Entecavir , Clorafabine , Gemcitabine HCL , Granisetron HCL , Ailamode , Bortezomib , Zoledronci Acid , Risedronate Sodium , Irinotecan , Paclitaxel , Docetaxel , Voriconazole , Fludarabine , Adrenaline
Weith Pharmaceutical (Shanghai) Technology Co., Ltd. is a leading Hi-Tech pharmaceutical company integrating R&D, production, sales, and trading of Active Pharmaceutical Ingredients (APIs) and Key Intermediates, covering the whole industrial chain.Weith Pharmaceutical is a wholly-invested subsidiary of Weith Group LLC.Weith Group LLC, headquarted in Boston, U.S.A is a versatile organization, striding in Pharmaceutical, Fine Chemial, Iron and Steel, Real Estate industries. The total capital of Weith Group exceeds 100 billion US dollars, ranking 246th in World Fortune 500, with 4, 000 workforce serving in worldwide. There are approximately 200 employees working in the Weith Pharmaceutical family, with 24 very experienced senior technical managers coming from the chemistry synthesis and biopharmaceutical fields. A strong R&D ability is the company€™s core competency for sustainable growth. Supported by advanced technology, Weith Pharmaceutical has been taking the lead position in the R&D and industrialization area in China. Wholly or partly invested by Weith Pharmaceutical, there are four production bases for APIs and Intermediates, two are GMP-compliant and two are FDA-approved facilities All production and procedures are compliant with the requirements of WHO GMP. To date, there are several APIs that have been approved by the SFDA and have been issued GMP certificates. The US FDA has completed an on-site pre- audit for several APIs. Some of APIs have registered DMF€™s and some of OPEN PART of DMF have been prepared well.To Weith Pharmaceutical, €œTechnology is productivity€, and the company allocates 10% of annual revenue to R&D and process optimization. Relying on key strengths in four plants, Weith Pharmaceutical converts newly developed technology into production. .
